Payment overview · 2025
General Payments
$240.44
13 reported records · 9 companies
Healthcare provider profile · identity verified
Lori Helgesen, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · VINCENT, OH · NPI 1700154929
Verified facts
What the public records show
CMS Open Payments records show Lori Helgesen, APRN received $240.44 in general payments during 2025 across 13 reported records.
PFIZER INC. accounted for 26.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Farxiga by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $64.17 | 26.7% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $40.56 | 16.9% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.56 | 13.5% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $20.45 | 8.5% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $19.38 | 8.1% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $18.21 | 7.6% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.10 | 6.7% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.24 | 6.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.77 | 5.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $240.44 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $44.45 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $44.45 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $44.45 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $40.56 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $32.56 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $32.56 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $20.45 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $19.38 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $18.21 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $16.10 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.24 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $15.24 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $15.24 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $15.24 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 44 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
44 | 44 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
108 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 472 | 126 |
| Losartan Potassium | Losartan Potassium | 296 | 86 |
| Levothyroxine Sodium | Levothyroxine Sodium | 271 | 69 |
| Amlodipine Besylate | Amlodipine Besylate | 235 | 70 |
| Lisinopril | Lisinopril | 193 | 62 |
| Pantoprazole Sodium | Pantoprazole Sodium | 190 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 178 | 54 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 164 | 52 |
| Omeprazole | Omeprazole | 160 | 48 |
| Gabapentin | Gabapentin | 138 | 39 |
| Furosemide | Furosemide | 136 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 128 | 41 |
| Eliquis | Apixaban | 108 | 23 |
| Metformin Hcl Er | Metformin Hcl | 108 | 32 |
| Potassium Chloride | Potassium Chloride | 106 | 39 |
| Trazodone Hcl | Trazodone Hcl | 92 | 36 |
| Sertraline Hcl | Sertraline Hcl | 84 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 82 | 19 |
| Alendronate Sodium | Alendronate Sodium | 80 | 30 |
| Ozempic | Semaglutide | 78 | 18 |
| Alprazolam | Alprazolam | 77 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 75 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 74 | 21 |
| Allopurinol | Allopurinol | 72 | 21 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 71 | 59 |
| Spironolactone | Spironolactone | 69 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 67 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 67 | 19 |
| Nifedipine Er | Nifedipine | 67 | 19 |
| Buspirone Hcl | Buspirone Hcl | 66 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 66 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 65 | 22 |
| Metformin Hcl | Metformin Hcl | 62 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 61 | 22 |
| Meloxicam | Meloxicam | 61 | 20 |
| Clonazepam | Clonazepam | 60 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 58 | 19 |
| Simvastatin | Simvastatin | 58 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 56 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 54 | 23 |
| Warfarin Sodium | Warfarin Sodium | 54 | 14 |
| Mirtazapine | Mirtazapine | 53 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 52 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 45 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 44 | 44 |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | 15 |
| Prednisone | Prednisone | 44 | 35 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 43 | 11 |
| Lorazepam | Lorazepam | 41 | 13 |
| Atenolol | Atenolol | 39 | suppressed |
| Methylprednisolone | Methylprednisolone | 39 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 39 | suppressed |
| Famotidine | Famotidine | 37 | 12 |
| Jardiance | Empagliflozin | 37 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 36 | 34 |
| Trulicity | Dulaglutide | 36 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | 11 |
| Carvedilol | Carvedilol | 33 | 13 |
| Ezetimibe | Ezetimibe | 33 | suppressed |
| Lovastatin | Lovastatin | 32 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 32 | 13 |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 29 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 28 | 12 |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Nystatin | Nystatin | 26 | 14 |
| Bupropion Xl | Bupropion Hcl | 25 | suppressed |
| Celecoxib | Celecoxib | 24 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 22 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 20 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 18 |
| Baclofen | Baclofen | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Repatha Sureclick | Evolocumab | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | 11 |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Phenobarbital | Phenobarbital | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Pentoxifylline | Pentoxifylline | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $240.44 · 13 records | PFIZER INC. | ABRYSVO, AIRSUPRA, Auvelity, CAPLYTA, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, GARDASIL 9, OTEZLA, PREVNAR 20, REPATHA, REXULTI, Tymlos, VAXELIS, VAXNEUVANCE | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error